ACADIA Pharmaceuticals (FRA:DR6) Short Interest


FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
76 GF Score
Price €20.55
GF Value €21.67
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:DR6 vs EWTX, CRNX, VKTX: Short Interest Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACADIA Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Short Interest falls into.


FRA:DR6
76GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of €20.55 is trading 5.2% below its estimated GF Value™ of €21.67. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

  • Short Interest:
  • GF Value™: €21.67 vs. price of €20.55 (5.2% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for FRA:DR6

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.55
Price
€21.67
GF Value